Fortress Biotech (FBIO) EBITDA Margin (2015 - 2026)
Fortress Biotech (FBIO) posted quarterly EBITDA Margin of 34.07% for Q4 2025, up 12314.0% year-over-year from N/an in Q4 2024, and up 11.8% quarter-over-quarter from 38.63% in Q3 2025.
Powered by 
Analysis
Fortress Biotech (FBIO) EBITDA Margin (2015 - 2026) Analysis & Trends
Fortress Biotech's EBITDA Margin history runs 11 years deep, the most recent figure standing at 34.07% for Q4 2025.
- In Q4 2025, EBITDA Margin rose 12314.0% year-over-year to 34.07%; the TTM figure through Dec 2025 stood at 117.64% (up 7344.0% YoY), while the FY2025 annual figure was 114.67%, up 7671.0% from the prior year.
- EBITDA Margin for Q4 2025 stood at 34.07%, up from 38.63% in the prior quarter.
- The five-year high for EBITDA Margin was 95.09% in Q4 2022, with the low at 27649.68% in Q2 2021.
- The 5-year median for EBITDA Margin is 248.79% (2025), against an average of 4544.47%.
- The sharpest annual moves came in 2021 and 2022: EBITDA Margin slumped 2738114 bps in 2021, then surged 2737040 bps in 2022.
- Fortress Biotech's EBITDA Margin stood at 106.01% in 2021, then surged by 190 bps to 95.09% in 2022, then tumbled by 235 bps to 128.56% in 2023, then slipped by 22 bps to 157.21% in 2024, then soared by 78 bps to 34.07% in 2025.
- Business Quant data shows FBIO's EBITDA Margin at 34.07% in Q4 2025, 38.63% in Q3 2025, and 243.01% in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.52 Bn | 133.66 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.69 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.63 Bn | 59.45 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 59.30 Bn | 54.16 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.41 Bn | 44.41 Bn | - | - |
| 6 | BeOne Medicines | 40.45 Bn | 35.35 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.29 Bn | 31.98 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 19.75% |
| 9 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | -0.36% |
| 10 | Fortress Biotech | 86.15 Mn | -110.42 Mn | 12.58 Mn | -53.46% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -53.46% |
| Dec 31, 2025 | -29.78% |
| Sep 30, 2025 | -38.63% |
| Jun 30, 2025 | -222.22% |
| Mar 31, 2025 | -169.85% |
| Dec 31, 2024 | -157.64% |
| Sep 30, 2024 | -151.04% |
| Jun 30, 2024 | -186.55% |
| Mar 31, 2024 | -280.63% |
| Dec 31, 2023 | -98.34% |
| Sep 30, 2023 | -39.59% |
| Jun 30, 2023 | -288.19% |
| Mar 31, 2023 | -473.63% |
| Dec 31, 2022 | -333.05% |
| Sep 30, 2022 | -306.96% |
| Jun 30, 2022 | -279.28% |
| Mar 31, 2022 | -197.58% |
| Dec 31, 2021 | -339.25% |
| Sep 30, 2021 | -236.77% |
| Jun 30, 2021 | -240.19% |